Colombia has new diagnostic algorithm for the Chagas Disease Implementation Pilot ProjectsColombia has new diagnostic algorithm for the Chagas Disease Implementation Pilot Projects
Colombia has new diagnostic algorithm for the Chagas Disease Implementation Pilot Projects[November 2016] The implementation Project for Chagas disease in Colombia is moving forward. After an epidemiological analysis, the partners confirmed the change of the diagnostic algorithm for the country's pilot projects. With the new algorithm, positive cases for Chagas are confirmed by a simpler procedure test.
“Towards Ending the Neglect?” DNDi releases update on its Paediatric HIV Programme“Towards Ending the Neglect?” DNDi releases update on its Paediatric HIV Programme
“Towards Ending the Neglect?” DNDi releases update on its Paediatric HIV Programme[July 2016] As the International AIDS Conference kicks off in Durban, the Drugs for Neglected Diseases initiative (DNDi) has released an update on its efforts to develop optimal child-adapted antiretroviral formulations. This document details some recent progress towards its final goal of developing “4-in-1” fixed-dose combinations using the World Health Organization (WHO) recommended treatment regimen for infants and young children. DNDi’s update also discusses some promising developments for treatment for children living with both HIV and tuberculosis (TB).
The global response to AMR must not fail to address the needs of neglected patientsThe global response to AMR must not fail to address the needs of neglected patients
The global response to AMR must not fail to address the needs of neglected patientsManica Balasegaram, Director, Global Antiobiotic Research and Development Partnership [June 2016] Far from being an apocalyptic fantasy, a post-antibiotic era in which common infections and minor injuries can kill has become a very real possibility. Of late, media headlines about ‘the end of the road’ for antibiotics have been plentiful. The latest case in May this year to receive a good deal of attention was of a patient in the US found to be carrying bacteria resistant to antibiotics of last resort. [Español] [Português]
AusTrade supports Epichem leishmaniasis research programmeAusTrade supports Epichem leishmaniasis research programme
AusTrade supports Epichem leishmaniasis research programmeDNDi and its partner Epichem are pleased to announce that the Australian Tropical Medicine Commercialisation Grants Programme (ATMCG), with the support of Australia’s Trade and Investment Ministry (AusTrade), are providing $250,000 for a project which is focused on developing new treatments for leishmaniasis. The name of the project is: “Novel compounds for the treatment of Leishmaniasis in humans and animals,” which will be led by PharmAust Limited’s (ASX:PAA) subsidiary Epichem in partnership with DNDi.
- African Eye Worm is Worse than it Looks: New Study Shows that the Disease Leads to Increased Mortality 27 October 2016
- Global Antibiotic Research and Development Partnership receives financial support from Swiss Government 22 September 2016
- “Towards Ending the Neglect?” DNDi releases update on its Paediatric HIV Programme 14 July 2016
- Celgene joins DNDi’s “Drug Discovery Booster” to accelerate discovery of new treatments for neglected diseases 15 June 2016
- DNDi, Mundo Sano and Chemo team up to register benznidazole in US and Latin America 8 June 2016
- Ärzteblatt: “Mehr Geld für die Forschung zu armutsbedingten Erkrankungen” 5 December 2016
- The Huffington Post: “This group helps fight devastating diseases the world ignores” 1 December 2016
- The Huffington Post: “This doctor gave up his shot at a cushy career to cure a little known-disease” 29 November 2016
- The Huffington Post: “How you can help stamp out a deadly disease” 22 November 2016
- The Star: “Act fast to get life-saving antivirals” 16 November 2016
- Essential medicines for universal health coverage by Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, Gyansa-Lutterodt M, Jing S, Luiza VL, Mbindyo RM, Möller H, Moucheraud C, Pécoul B, Rägo L, Rashidian A, Ross-Degnan D, Stephens PN, Teerawattananon Y, ’t Hoen EFM, Wagner AK, Yadav P, Reich MR. The Lancet, November 2016
- Evaluation of parameters impacting drug susceptibility in intracellular T. cruzi assay protocols by Yang G, Lee N, Ioset JR, No JH. Journal of Biomolecular Screening, October 2016
- Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage by Francisco AF, Jayawardhana S, Lewis MD, White KL, Shackleford DM, Chen G, Saunders J, Osuna-Cabello M, Read KD, Charman SA, Chatelain E, Kelly JM. Scientific Reports, October 2016
- A DBS method for quantitation of the new oral trypanocidal drug fexinidazole and its active metabolites by Filali-Ansary A, Augé C, Abgrall A, Souchaud M, Pellissier F, Valverde Mordt O, Blesson S, Sanderink JG. Bioanalysis, October 2016
- Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: Phase II randomized trial by Wasunna M, Njenga S, Balasegaram M, Alexander N, Omollo R, Edwards T, Dorlo TPC, Musa B, Sharaf Ali MH, Elamin MY, Kirigi G, Juma R, Anke E. Kip, Schoone GJ, Hailu A, Olobo J, Ellis S, Kimutai R, Wells S, Khalil EAG, Strub Wourgaft N, Alves F, Musa A. PLOS Neglected Tropical Diseases, September 2016
- 10º ENIFarMed
Encontro Nacional da Inovação em Fármacos e MedicamentosOctober 17-18, 2016 São Paulo, Brazil DNDi Latin America presented on Lead Optimization in Latin America and hepatitis C.
- ASTMH 2016
American Society of Tropical Medicine and Hygiene (ASTMH), 65th Annual MeetingNovember 13-17, 2016 Atlanta, Georgia USA DNDi presented in symposia on sleeping sickness and Chagas disease, they also co-authored poster presentations on filarial diseases.
- WorldLeish 6
6th World Congress on LeishmaniasisMay 16-20, 2017 Toledo, Spain The WHO ColIaborating Centre for Leishmaniasis at the Instituto de Salud Carlos III, Madrid and the Drugs for Neglected Diseases initiative, Geneva have joined efforts to co-organize the WorldLeish-6 Congress.